PMID 34815532
Applying the modified Response Evaluation Criteria in Solid Tumors (mRECIST), we observed that patients with higher intracellular GSH levels responded worse to neoadjuvant chemotherapy, as indicated by MRI scans, than those with lower intracellular GSH levels (Fig
CB6F1 female mice were obtained from the National Institute on Aging aged rodent colony at 15 months of age
The use of a BPC peptide salt according to any of the claims 1 to 9 for the preparation of a compatible, storage-stable pharmaceutical composition according to claim 10 for the treatment of:disturbances connected with either nitric oxide (NO) formation or impaired NO-system functions, in particular, hypertension, angina, impotence, circulatory and septic shock, stroke, inflammation, respiratory distress syndrome, adhesion and aggregation of platelets and leukocytes, endothelial dysfunction, gastrointestinal lesions, peristalsis disturbances, diabetes pancreatitis, hypotension and Parkinson's disease;dysfunctions or hyperfunctions of somatosensory nerves, in particular, sensory neuropathy, postherpetic neuralgia, atopic dermatitis, impaired healing of injured tissue, acquired cold and heat urticaria, psoriasis, bullous pemphigoid, eczema, photodermatoses, chronic arthritis, gastrointestinal lesions and specific or non-specific hyperreactivity of upper and lower respiratory tracts (asthma, rhinitis);endothelium disturbances;wounds, ulcers;conditions relating to acute and/or chronic inflammation, in particular, chronic arthritis, and disorders related with delayed type of hypersensitivity, and gastrointestinal lesions;liver disorders, organ lesions induced by free radicals specifically caused by irradiation;disorders connected with cathecholaminergic system disturbances, in particular, schizophrenia, amphetamine challenge effects, drug abuse;stress related conditions;acute pancreatitis
This applies to Wegovy, Mounjaro, Ozempic, Saxenda, Victoza, Trulicity, Byetta, and Bydureon
